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Poly(ethyleneglycol) (PEG)isthemostwidelyusedpolymerindeliveringanticancer drugsclinically. PEGylation (i.e.,thecovalent
attachment of PEG) of peptides proteins, drugs, and bioactives is known to enhance the aqueous solubility of hydrophobic drugs,
prolongcirculationtime,minimizenonspeciﬁcuptake,andachievespeciﬁctumortargetabilitythroughtheenhancedpermeability
and retention eﬀect. Numerous PEG-based therapeutics have been developed, and several have received market approval. A vast
amount of clinical experience has been gained which has helped to design PEG prodrug conjugates with improved therapeutic
eﬃcacy and reduced systemic toxicity. However, more eﬀorts in designing PEG-based prodrug conjugates are anticipated. In light
of this, the current paper highlights the synthetic advances in PEG prodrug conjugation methodologies with varied bioactive com-
ponents of clinical relevance. In addition, this paper discusses FDA-approved PEGylated delivery systems, their intended clinical
applications, and formulations under clinical trials.
1.Introduction
The ﬁeld of drug delivery system (DDS) utilizing polymeric
carrier, which covalently conjugates molecule of interest,
plays an important role in modern therapeutics [1, 2]. Such
polymer-based drug entities are now termed as “polymer
therapeutics” and include nanomedicine class that has
become immensely critical in recent years [3–5]. The objec-
tives for designing a polymer therapeutics are primarily to
improve the potential of the respective drug by (i) enhancing
water solubility, particularly relevant for some drugs with
low aqueous solubility, (ii) stability against degrading enzy-
mes or reduced uptake by reticulo-endothelial system (RES),
and (iii) targeted delivery of drugs to speciﬁc sites of action
in the body [1, 6].
Poly(ethyleneglycol) (PEG) is the most commonly used
nonionicpolymerintheﬁeldofpolymer-baseddrugdelivery
[1]. Due to high aqueous solubility, PEG polymer is con-
sidered as a versatile candidate for the prodrug conjugation.
Ringdorf was the ﬁrst to propose the rational model for
pharmacologically active polymers in 1975 [7]. An ideal pro-
drug model typically consists of multiple components
(Figure 1):
(i) polymer as a carrier;
(ii) drug, peptide, or protein as a biological active com-
ponent;
(iii) spacer molecule or targeting moiety.
PEGylation,thecovalentattachmentofPEGtomolecules
of interest, has become a well-established prodrug delivery
system [8, 9]. PEGylation was ﬁrst reported by Davies and
Abuchowski in the 1970s for albumin and catalase modi-
ﬁcation. Since then the procedure of PEGylation has been
broadened and developed thereafter tremendously [10–16].
The remarkable properties of the biologically inert (biocom-
patible)PEGpolymerderivefromitshydrophilicityandﬂex-
ibility. PEG is also considered to be somewhat hydrophobic
due to its solubility in many organic solvents. Most used2 Journal of Drug Delivery
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PEGs for prodrug modiﬁcation are either monomethoxy
PEG or dihydroxyl PEG (Figure 2)[ 7].
Typically, most of the PEG-based prodrugs have been
developed for the delivery of anticancer agents such as pacli-
taxel, methotrexate, and cisplatin. High-molecular-weight
prodrugs containing cytotoxic components have been devel-
oped to decrease peripheral side eﬀects and to obtain a more
speciﬁc administration of the drugs to the cancerous tissues
[17]. Favorably, a macromolecular antitumor prodrug is
expected to be stable in circulation and should degrade only
after reaching the targeted cells or tissues. PEG-drug con-
jugates can therefore be tailored for activation by extra-
or intracellular enzymes releasing the parent drug in situ
(Figure 3)[ 7]. In this paper, we represent an overview on the
advances of PEG prodrug conjugates which are being cur-
rently used as therapeutics. A short discussion with partic-
ular emphasis on the derivatives in clinical practice or still
under clinical trials is also provided.
2. Properties of PEG
PEG in its most common form is a linear or branched poly-
ether terminated with hydroxyl groups. PEG is synthesized
byanionicpolymerizationofethyleneoxideinitiatedbynuc-
leophilic attack of a hydroxide ion on the epoxide ring. Most
useful for polypeptide modiﬁcation is monomethoxy PEG
(mPEG).Ontheotherhand,mPEGissynthesizedbyanionic
ring opening polymerization initiated with methoxide ions.
Successful conjugation of PEG with biomolecule depends
upon the chemical structure, molecular weight, steric hin-
drance, and the reactivity of the biomolecule as well as the
polymer. In order to synthesize a bioconjugate, both chem-
ical entities (i.e., the bioactive as well as the polymer) need
to possess a reactive or functional group such as –COOH,
–OH, –SH, or –NH2. Therefore, the synthetic methodology
to form a conjugate involves either protection or deprotec-
tion of the groups [18].
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Figure 3: A schematic illustration of prodrug concept.
3.PEG-BasedNanocarrier
ArchitecturesandDesigns
There is need to design simple and yet appropriate PEG-con-
jugation methodology. Most commonly used strategies for
conjugation involve use of both coupling agents such as
dicyclohexyl carbodiimide (DCC) and 1-ethyl-3-(3-dime-
thylaminopropyl)carbodiimide (EDC) or use of N-hydro-
xysuccinimide (NHS) esters. Chemical conjugation of drugs
or other biomolecules to polymers and its modiﬁcations can
form stable bonds such as ester, amide, and disulphide. The
resulting bond linkage should be relatively stable to prevent
drug release during its transport until it reaches the target.
Covalent bonds (e.g., ester or amide) are comparatively
stable bonds and could deliver the drug at the targeted site.
However, in some instances such bonds may not easily
release targeting agents and peptides under the inﬂuence of
acceptableenvironmentalchanges[19].Inthepast,PEGpro-
drugs have been designed mostly for the delivery of anti-
cancer agents due to its overall implications in the treatment.
However it should be noted that PEG-antitumor prodrug is
expected to be stable during circulation and degrade/hydro-
lyze only on reaching the targeted site. PEG-drug conjugates
can therefore be tailored to release the parent drug in situ on
activation by extra- or intracellular enzymes or pH change.
PEG has limited conjugation capacity since it possesses
only one (two in case of modiﬁed PEGs) terminal functional
groupattheendofthepolymerchain.Toovercomethislimi-
tation of PEG, coupling amino acids, such as bicarboxylic
amino acid and aspartic acid, to the PEG has been proposed
[20, 21]. Such derivatization increases the number of active
groupsoftheoriginalPEGmolecule.Usingthesamemethod
with recursive derivatization, dendrimeric structures have
also been achieved at each PEGs extremity. However, in the
study the authors encountered low reactivity of the bicar-
boxylic acids groups towards arabinofuranosylcytosine (Ara-
C) binding due to steric hindrance between two Ara-C mole-
cules on conjugation with neighboring carboxylic moieties.Journal of Drug Delivery 3
It was suggested that this eﬀect might be overcome by
incorporating the dendrimer arms with an amino alcohol
(H2N–[CH2–CH2–O]2–H).
PEG polymers with hydroxyl terminals can be easily
modiﬁed by aliphatic chains molecules or small amino acids.
For example, antitumor agent 1-β-D-Ara-C was covalently
linked to varying molecular weight –OH terminal PEGs
through an amino acid spacer in order to improve the in
vivostabilityandbloodresidencetime[22].Conjugationwas
carried out with one or two available hydroxyl groups at the
polymer’s terminals. Furthermore, to increase the drug load-
ing of the polymer, the hydroxyl groups of PEG were func-
tionalized with a bicarboxylic amino acid to form a tetra-
functional derivative. Finally, the conjugates with four or
eight Ara-C molecules for each PEG chain were prepared
(Figure 4).TheauthorsinvestigatedsterichindranceinPEG-
Ara-C conjugates using molecular modeling to investigate
themostsuitablebicarboxylicaminoacidwiththeleaststeric
hindrance. Typically, hydroxyl groups of PEG are activated
by p-nitrophenyl chloroformate to form a stable carbamate
linkage between PEG and amino acid. The degree of PEG
hydroxyl group activation with p-nitrophenyl chloroformate
was determined by UV analysis of the p-nitrophenol released
from PEG-p-nitrophenyl carbonate after alkaline hydrolysis.
Activated PEG was further coupled with amino acid and
the intermediate PEG-amino acid was linked to Ara-C by
EDC/NHS activation.
3.1. PEG N-Hydroxysuccinimide (NHS) Esters and Coupling
Methods. PEG-NHS esters are readily available which are
reactive with nucleophiles to release the NHS leaving group
and forms an acylated product [23]( Figure 5(a)). NHS is
a choice for amine coupling because of its higher reactivity
at physiological pH reactions in bioconjugation synthesis.
In particular, carboxyl groups activated with NHS esters are
highly reactive with amine nucleophiles and are very com-
mon entity in peptides and proteins. Polymers containing
reactive hydroxyl groups (e.g., PEG) can be modiﬁed to
obtainanhydridecompounds.Ontheotherhand,mPEGcan
beacetylatedwithanhydridestoformanesterterminatingto
free carboxylate groups (Figure 6).
The reactive PEG and its derivatives succinimidyl suc-
cinate and succinimidyl glutamate are used for conjugation
with drugs or proteins. The coupling reactions involving
aminegroupsareusuallyoftwotypes:(a)acylation,(b)alky-
lation. These reactions are comparatively eﬃcient to form a
stable amide bond. In addition, carbodiimide coupling reac-
tionsorzerolengthscrosslinkersarewidelyusedforcoupling
or condensation reactions. Most of the coupling methodolo-
gies involve use of heterobifunctional reagent to couple via
modiﬁed lysine residues on one protein to sulphydryl groups
on the second protein [24], while modiﬁcation of lysine
residues involves the use of a heterobifunctional reagent
comprising an NHS functional group, together with a malei-
mide or protected sulphydryl group. The linkage formed is
either a disulphide bridge or as a thioether bond, depending
if the introduced group is either a sulphydryl or maleimide,
respectively. The thiol group on the second protein may be
an endogenous free sulphydryl, or chemically introduced by
modiﬁcation of lysine residues.
4.PEGProdrugConjugatesas
Drug-Delivery Systems
In general, low-molecular-weight compounds diﬀuse into
normal and tumor tissue through endothelia cell layer of
blood capillaries [7]. Conjugation of low-molecular-weight
drugs with high-molecular-weight polymeric carriers results
in high-molecular weight prodrugs (Figure 1). However,
such conjugation substantially alters the mechanism of cel-
lular internalization and accumulation. High-molecular-
weight drugs are internalized mainly by endocytosis, which
is a much slower internalization process over to simple diﬀu-
sion. Hence in case of endocytosis higher drug concentration
outside the cell is required to produce the same cellular eﬀect
as corresponding low-molecular-weight drug [7]. Therefore,
higher-molecular-weight prodrugs displays lower speciﬁc
activity compared to its free form of drugs. For example,
polymeric anticancer prodrugs are generally less toxic when
compared with its free form, yet require substantially higher
concentrations inside the tumor to be cytotoxic. Compen-
sation for this decrease in drug eﬃcacy can be achieved by
targeting a polymeric drug to the speciﬁc organ, tissue, and/
or cell [7].
Following two approaches is generally used to target
polymeric anticancer drugs to the tumor or cancer cells [25,
26]:
(1) passive targeting,
(2) active targeting.
4.1. Passive Drug Targeting: The EPR Eﬀect. Passive targeting
is a drug delivery approach in which drugs are delivered
to the targeted site by conjugating with polymer which
releases the drug outside the targeted site due to altered envi-
ronmental conditions (Figure 6(a)). Tumors and many in-
ﬂamed areas of body have hyperpermeable vasculature and
poor lymphatic drainage which passively provides increased
retention of macromolecules into tumor and inﬂamed area
of body [27–30]. This phenomenon is called enhanced per-
meability and retention (EPR) eﬀect [27]. It constitutes one
of the practical carrier-based anticancer drug delivery strate-
gies. EPR eﬀect is primarily utilized for passive targeting due
to accumulation of prodrug into tumor or inﬂamed area.
Low molecular drugs covalently coupled with high-mole-
cular-weight carriers are ineﬃciently eliminated due to ham-
pered lymphatic drainage and therefore accumulate in tu-
mors. While EPR eﬀect enhances the passive targeting ability
due to higher accumulation rate of drug in tumor and sub-
sequently due to accumulation, prodrug slowly releases drug
molecules which provide high bioavailability and low sys-
temic toxicity [30].
Passive accumulation of macromolecules such as PEG
and other nanoparticles in solid tumors is a phenomenon
which was probably overlooked for several years as a poten-
tial biological target for tumor-selective drug delivery.4 Journal of Drug Delivery
PEG
PEG
+ O C
O O
O O
O C O PEG
(1)
(2)
2
C O
2
NO2 NO2
CH2Cl
H2O/
Cl
2
CH2CN
CH2Cl2
Et3N
Et3N
OH OH
NH CH
CONHS
CH2CH2CH2CONHS
Ara C
Pyridine
EDC/NHS
AD = amino adipic acid
Amino adipic acid
PEG C O
2
NH CH
COOH
CH2CH2CH2COOH
PEG-AD2-Ara-C
(a)
C O PEG
C H
2
H2O/CH2CN
Et3N
PEG C O
2
NH CH
CONHS
CH2CH2CH2CONHS
Amino adipic acid
NH CH
COOH
CH2CH2CH2COOH
COOH
CH2CH2CH2COOH
CH2CH2CH
CH
2 CONH
CH2CH2CH2 CONH
CONH
C O PGE
C H
2
17
NH CH
COOH
CH2CH2CH2CONHS
CONHS
CH2CH2CH2CONHS
CH CONH
O
O
O
Ara-C
Pyridine
PEG-A2-AD4-Ara-C8
(b)
Figure 4: Synthetic schemes for PEG10,000-AD2-Ara-C4 (7) (a) and PEG10,000-AD2-AD4-Ara-C8 (8) conjugates (b). The antitumour agent 1-
b-D-arabinofuranosylcytosine(Ara-C)wascovalentlylinkedtovaryingmolecularweight–OHterminalPEGsthroughanaminoacidspacer
in order to improve the in vivo stability and blood residence time (reproduced from [22]).
TheexistenceoftheEPReﬀectwasexperimentallyconﬁrmed
by David et al., for macromolecular anticancer drug delivery
systems [31]. Furthermore, passive targeting increases the
concentration of the conjugate in the tumor environment
and therefore “passively” forces the polymeric drug to enter
the cells by means of the concentration gradient between the
intracellularandextracellularspacesandthereforeisnotvery
eﬃc i e n t .T h em o r ee ﬃcient way to provide targeting is by
“active targeting” [32].
4.2. Active Targeting. Active targeting approach is based on
interaction between speciﬁc biological pairs (e.g., ligand re-
ceptor, antigen antibody, enzyme substrate) (Figure 6(a))
[33]. Active targeting is achieved by attaching targeting
agents that bind to speciﬁc receptors on the cell surface—to
the prodrug by a variety of conjugation chemistries. Most
widelyusedtargetingmoietiesarepeptideligands,sugarresi-
dues, antibodies, and aptamers speciﬁc to particular recep-
tors, selectins, antigens, and mRNAs expressed in targetedJournal of Drug Delivery 5
+
+
N O O
O
O
N O O
OH O
NHR
Amine component NHS ester derivative Amide bond NHS leaving group
R
R
R–NH2
(a)
+
EDC
O
O O
O
O O
n
NH R
O O
O O
R-OH
+ O
O
n
O
O O
n
O R
O O
O O
Succinylated mPEG mPEG with amide bond
Organic solvent
Succinylated mPEG mPEG with ester bond
H3C H3C
H3C O
H3C
n
OH
OH
R-NH2
DCC or EDC·HCl
(b)
Figure 5: (a) NHS esters compounds react with nucleophiles to release the NHS leaving group and form an acetylated product. (b) PEG can
be succinylated to form –COOH group, which can further form amide or ester bond with biomolecules.
cells or organs. The targeted anticancer LHRH-PEG-CPT
conjugate is an example of such targeted anticancer drug
delivery system [7]. In this system, LHRH peptide is used
as a targeting moiety to the corresponding receptors over-
expressed in several cancer cells, PEG polymer—as a carrier
and CPT—as an anticancer drug. Interaction of these tar-
geting moieties to their target molecule results in uptake of
the drug by two main approaches: (i) internalization of the
whole prodrug or (ii) internalization of the drug into tar-
getedcellsbyvariousendocytosisandphagocytosispathways
[34].
(i) Internalization of the Prodrug. In this system, the drug
is cleaved intracellularly after endocytosis. The internalized
prodrug exhibits pharmacological activity on reaching the
cytosol or the nucleus, which are the sites of action of intra-
cellularly active drugs. This process can be divided into sev-
eral distinct steps as schematically presented in Figure 6(b).
Interaction of a targeted prodrug with a corresponding re-
ceptor initiates receptor-mediated endocytosis by formation
of an endocytic vesicle and endosomes-membrane-limited
transportvesicleswithapolymericdeliverysysteminside[6].
The activity of the drug is preserved during the intracellular
transport as the membrane-coated endosome prevents drugs
from degradation by cellular detoxiﬁcation enzymes. Endo-
somes fuses with lysosomes forming secondary lysosomes. If
the drug-polymer conjugate is designed by incorporating an
enzymatically cleavable bond then the drug is released from
the polymer-drug conjugate by the lysosomal enzymes and
might exit a lysosome by diﬀusion. The advantage of this ap-
proach is a high local drug concentration with a potential
increase in eﬃcacy [30].
(ii) Internalization of the Drug. In this system, the drug con-
jugate is cleaved extracellularly.
The microenvironment of tumors has been reported to
be slightly acidic in animal models and human patients and
the pH value in tumor tissue is often0.5–1.0 units lower than
in normal tissue.
5. Approaches andApplications
5.1. Polymer Conjugates of Therapeutically Relevant Proteins.
The potential value of proteins such as antibodies, cyto-
kines, growth factors, and enzymes as therapeutics has been
recognized for years. However, successful development and
application of therapeutic proteins are often impeded by
severaldiﬃculties,forexample,shortcirculatingt1/2,lowsta-
bility, costly production, poor bioavailability, and immuno-
genic and allergic potential. An elegant method to overcome
most of these diﬃculties is the attachment of PEG chains
onto the surface of the protein. PEGylation of the native pro-
tein generally masks the protein’s surface, inhibits antibodies
or antigen processing cells, and reduces degradation by pro-
teolytic enzymes [6]. In addition, PEGylation of the native
protein increases its molecular size and as a result prolongs
the half-life in vivo, which in turn allows less frequent admi-
nistration of the therapeutic protein.6 Journal of Drug Delivery
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Figure 6: (a) Active and passive targeting by nanocarriers [35]; (b) (1) polymer-conjugated drug is internalized by tumor cells through
receptor-mediated endocytosis following ligand-receptor docking, (2) transport of DDS in membrane limited organelles; (3) fusion with
lysosomes; (4) the drug will usually be released intracellularly on exposure to lysosomal enzymes or lower pH (pH 6.5–<4.0) [31]. If the drug
is bound to the polymer by an acid-sensitive linker then the extracellular release of drug takes place, especially if the drug is trapped by the
tumor for longer period of time.
The most common chemical approach for preparing
PEG-protein conjugates has been by coupling –NH2 groups
of proteins and mPEG with an electrophilic functional group
[36]. Such conjugate reactions usually result in formation
of polymer chains, covalently linked to a globular protein
in the core. Figures 7(a) and 7(b) illustrate the commonly
used methods of mPEG-based protein modifying reagents.
Derivatives 1 and 2 contain a reactive aryl chloride residue,
which is displaced by a nucleophilic amino group by a
reaction with peptides or proteins, as shown in Figure 7(b).
Derivatives1and2areacylatingreagents,whereasderivatives
3 – 1 1c o n t a i nr e a c t i v ea c y lg r o u p sr e f e r e n c e da sa c y l a t i n g
agents. Protein modiﬁcation with all of these agents results
in acylated amine-containing linkages: amides derived from
active esters 3–6 and 11 or carbamates derived from 7–10.
Alkylating reagents 12 and 13 react with proteins forming
secondary amine conjugation with amino-containing resi-
dues. As represented in Figure 7(a), tresylate 12 alkylates di-
rectly, while acetaldehyde 13 is used in reductive alkylation
reactions. Numbers 1–13 represent the order in which these
activated polymers were introduced [6, 36].
Adagen (pegademase bovine), used for the treatment of
severecombinedimmunodeﬁciencydisease(SCID),isdevel-
oped using PEG polymer. PEG chemistry may results in side
reaction or weak linkages upon conjugation with polypep-
tides and low-molecular-weight linear PEGs (≤12kDa). It is
prepared by ﬁrst reacting mPEG (Mw 5000Da) with suc-
cinic anhydride spacer. The resulting carboxylic group of
PEG succinic acid is activated with N-hydroxysuccinimide
(NHS) by using carbodiimide coupling agents. The NHS
group is displaced by nonspeciﬁc reaction with nucleophilic
amino acid side chains [37]. Another PEG prodrug of Enzon
(Oncaspar) is also synthesized by the use of PEG suc-
cinimidyl succinate [37]. The PEG ester and thioesters are
highly susceptible tohydrolysis and thus modiﬁcation occurs
primarily at the amines forming amides. The PEGylated
CERA protein conjugate, a product of Hoﬀmann-LaRoche
(Mircera) is synthesized by attachment of an NHS-activated
monomethoxy PEG butanoic acid to lysine 46 and 52 on ery-
thropoietin (EPO) [38, 39]. Also, Hoﬀman-La Roche, Inc.’s
peginterferon α2a (Pegasys) is prepared by conjugating PEG
with the side chain and N-terminal amine groups of lysine
spacer, forming a biscarbamate. Then on activation of the
carboxylic acid with NHS, it helps the branched PEG chain
linker form stable amide bonds with 11 possible lysine resi-
dues. Monosubstituted conjugate can also be synthesized by
the same reaction process by limiting the amount of PEG
chain linker used in the conjugation step. While, PEG-Intron
by Schering-Plough (peginterferon α2b) is a covalent con-
jugate of interferon alfa-2b linked to a single unit of Mw
12000 PEG [40] is a covalent conjugate of interferon alfa-2b
linkedtoasingleunitofMw12000PEG.Theinterferoncon-
jugates are synthesized by condensing activated PEG, where-
in a terminal hydroxy or amino group can be replaced by an
activated linker, and reacting with one or more of the free
amino groups in the interferon (Figure 8). Condensation
withonlyoneaminogrouptoformamonoPEGylatedconju-
gate is a prime feature of this synthesis process.
In other instance, pegvisomant (Somavert) prodrug con-
jugate is synthesized by covalent attachment of four to six
Mw 5000Da PEG units via NHS displacement to several
lysine residues available on hGH antagonist B2036, as well
as the N-terminal phenylalanine residue is used for acro-
megaly treatment [41–43]. Similarly, Amgen’s pegﬁlgrastim
(Neulasta) is used to decrease febrile neutropenia mani-
fested infection and this prodrug is a covalent conjugation
of Mw 20000Da monomethoxy PEG aldehyde by reductive
amination with the N-terminal methionine residue of the
ﬁlgrastimprotein[44].Ontheotherhand,Krystexxa(peglo-
ticase) by Savient, used for the treatment of chronic gout,Journal of Drug Delivery 7
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is synthesized by using PEG p-nitrophenyl carbonate ester
[45]. The primary amine lysine side chain is replaced by p-
nitrophenol to form carbamates, which are further subjected
to decrease hydrolysis under mild basic conditions. From
the total of 28-29 lysines, approximately 12 lysines on each
subunit of urate oxidase are surface accessible in the native
tetrameric form of the complete enzyme. In fact, due to the
close proximity of some of the lysine residues, PEGylation of
one lysine may sterically hinder the addition of another PEG
chain [45, 46].
5.2. PEG-Drug Conjugates. PEGylation of drugs does inﬂu-
ence the pharmacokinetic properties of drugs and drug car-
riers and therefore is emerging as an important area in phar-
maceutics. PEG has been successful for protein modiﬁcation
but in the case of low-molecular-weight drugs it presents
a crucial limit, the low drug payload accompanying the
available methoxy or diol forms of this polymer. This int-
rinsic limitation had for many years prevented the develop-
ment of a small drug-PEG conjugate, and also because the
conjugatesextravasationintotumorsbyEPReﬀectisdirectly8 Journal of Drug Delivery
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conjugated to a protein allows the protein to retain at least a portion of the activity level of its biological activity when not conjugated; with
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proportional to the conjugate’s molecular weight. Unfortu-
n a t e l y ,i nc a s eo fP E Gt h eu s eo fl a r g e rp o l y m e rd o e sn o t
correlate well with an increase in the amount of drug selec-
tively delivered into the tumor. In case of PEG, the number
of available groups for drug coupling does not change with
the length of polymeric chain, as happens instead with other
polymers (e.g., polyglutamic acid, and dextran) or copoly-
mers (e.g., HPMA). The latter can have several functional
groupsalongthepolymericbackbone:longerpolymerchains
correspond to an increased number of functional groups
[22, 47–49].
A few studies have been conducted recently to overcome
the low PEG loading by using multiarm PEGs either bran-
ched at the end chain groups or coupling on them small
dendron structures (Figure 9)[ 47, 49–51]. Such multiarm
PEG conjugates have recently entered phase I clinical trials
[52]. This compound was obtained by coupling a 4-arm PEG
of 40kDa with the camptothecin derivative SN38, through a
spacer glycine (Figure 10). The coupling strategy was deve-
loped to link selectively the 20-OH group of SN38, thus
preservingtheEringofSN38intheactivelactoneformwhile
leaving the drug 10-OH-free [53].
Design and synthesis of nontargeted or antibody tar-
geted biodegradable PEG multiblock coupled with N2,N5-
diglutamyllysine tripeptide with doxorubicin (Dox) attached
through acid-sensitive hydrazone bond has also been
reported [54–57]. PEG activated with phosgene and NHS
was reacted with –NH2 groups of triethyl ester of tripeptide
N2,N6-diglutamyllysine to obtain a degradable multi-block
polymer. The polymer was converted to the corresponding
polyhydrazidebyhydrazinolysisoftheethylesterwithhydra-
zine hydrate. On the other hand, the nontargeted conjugate
was prepared by direct coupling of Dox with the hydrazide
PEG multi-block polymer. Whereas the antibody-targeted
conjugates, a part of the polymer-bound hydrazide group,
was modiﬁed with succinimidyl 3-(2-pyridyldisulfanyl) pro-
panoate to introduce a pyridyldisulfanyl group for subsequ-
ent conjugation with a modiﬁed antibody. Dox was coupled
to the remaining hydrazide groups using acid-labile hydr-
azone bonds to obtain a polymer precursor. In addition,
humanimmunoglobulinIgGmodiﬁedwith2-iminothiolane
was conjugated to the polymer by substitution of the 2-pyri-
dylsulfanyl groups of the polymer with –SH groups of the
antibody. It was demonstrated that Dox was rapidly released
from the conjugates when incubated in phosphate buﬀer at
lysosomal pH 5 and 7.4 (blood).
5.3. Incorporation of Spacers in Prodrug Conjugates. To cons-
truct a prodrug, various spacers have been incorporated
along with the polymers and copolymers to decrease the
crowding eﬀect, to increase the reactivity, and reduce stericJournal of Drug Delivery 9
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mPEG-(dendron)-(drug)4 4arm-PEG-(drug)4
≪
Figure 9: Schematic representation of higher steric entanglement in PEG dendrons with respect to multiarm PEGs (reproduced from [52]).
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Figure 10: ENZ-2208: 4◦K4 arm-PEG-(SN38)4 (reproduced from
[53]).
hindrance [6, 58]. The application of a spacer arm can
enhance ligand-protein binding and also provide multiple
binding sites. Ideal spacer molecules possess the following
characteristics:
(1) stable during conjugate transport,
(2) adequate drug conjugation ability and,
(3) being able to release the bioactive agent at an appro-
priate site of action.
Amino acid spacers such as alanine, glycine, and small pep-
tides are most commonly used due to their chemical versatil-
ity for covalent conjugation and biodegradability. Heterobi-
functionalcouplingagentscontainingsuccinimidylhavealso
been used frequently as spacers.
Polymer spacers are used to enhance the conjugation
ratio of an antibody with a drug by introducing them bet-
ween the targeting antibody and the drug. The use of an
intermediate polymer with drug molecules carried in its side
chains increases the potential number of drug molecules able
to attach to that antibody by modiﬁcation of only a mini-
mum amount of existing amino acid residues (Figures 7(a)
and 7(b))[ 59].
6. PEG Therapeutics: ClinicalApplicationsand
Challenges for Development
PEG-based therapeutics were initially dismissed as interest-
ing, but impractical to be translated in clinical setups. How-
ever, a growing number of products have shown that they
can satisfy the stringent requirements of regulatory authority
approvals (Table 1). Clinically used PEG conjugates are des-
cribed below.
6.1. PEG-Proteins Conjugate
6.1.1. Adagen (mPEG per Adenosine Deaminase). Enzon’s
Adagen was among the ﬁrst few PEG-protein conjugates to
enter the clinic with FDA approval in 1990 [37]. It is used
as a placement therapy to treat severe combined immun-
odeﬁciency (SCID) disease. SCID is an autosomal recessive
genetic disorder caused by adenosine deaminase deﬁciency.
It is usually fatal in children unless the patient is kept in
protective isolation or undergoes a bone marrow transplant.
As an alternative, Adagen is administered intramuscularly
every 7 days. It is a replacement therapy and is repeated for
the rest of the life by the patients following the dosing sche-
dule: 10Ukg−1,1 5Uk g −1,a n d2 0Uk g −1 for the ﬁrst three
doses, and the weekly maintenance dose of 20Ukg−1.H o w -
ever, immune related problems have been reported for pega-
demase and its long-term treatment beneﬁts are yet to be
elucidated. Also, the high cost of treatment ($200,000–
$300,000 per annum per patient) is an obvious disadvantage
[60–62].
6.1.2. Oncaspar (mPEG-L-Asparaginase). Oncaspar (pega-
spargase) is an antineoplastic drug from Enzon Pharmaceu-
ticals Ltd. and was approved by FDA in 1994. Oncaspar is10 Journal of Drug Delivery
Table 1: PEG therapeutic systems with in the market or clinical development.
Product name Description Clinical use Route of admin. Stage
PEG-protein conjugates
Oncaspar PEG-asparaginase Acute lymphocytic leukaemia iv/im Market
Adagen PEG-adenosine deaminase Severe combined immune deﬁciency
syndrome im Market
Somavert PEG-HGH antagonist Acromegaly sc Market
PEGIntron PEG-Interferon alpha 2b Hepatitis C Hepatitis C sc Market
NeulastaTM PEG-rhGCSF Chemotherapy Chemotherapy-induced neutropenia sc Market
Pegasys PEG-interferon alpha 2a hepatitis C Hepatitis C sc Market
CimziaTM PEG-anti-TNF Fab Rheumatoid arthritis, Crohn’s disease sc Market
Mircera PEG-EPO Anaemia associated with chronic
kidney disease iv/sc Market
Puricase PEG-uricase Gout iv Market
Macugen PEG-aptamer Age-related macular degeneration Intraviteal Market
PEG-drug conjugates
NKTR-102 PEG-irinotecan Cancer-metastatic breast iv Phase II
PEG-SN38 Multiarm PEG-camptothecan
derivative Cancer-various iv Phase II
NKTR-118 PEG-naloxone Opioid-induced constipation Oral Phase II
a PEG-modiﬁed entity of the enzyme L-asparaginase and
is used for the treatment of acute lymphoblastic leukaemia
[63]. PEGylation was attempted to overcome several factors
limiting the utility of asparaginase as therapeutic agent such
as high clearance, immunologic factors such as antibodies to
asparaginase owing to bacterial protein and also inactivation
due to conversion to asparagine via asparagine synthetase.
Also, the immunological side eﬀects such as hypersensitivity
reactions (up to 73%) were major factors that limited clinical
utility of L-asparaginase [64].
Pegaspargase was developed in the 1970–1980 while it
was translated in the clinical trials in the 1980. Taking clues
from the preclinical studies, a series of systematic clinical
studies revealed the eﬀectiveness of the pegaspargase as com-
pared to its non-PEG-grafted parent drug [65, 66]. Clinical
trials demonstrated safety in terms of fewer incidence of
hypersensitivity reactions and prolonged duration of action.
T h et r i a l sd e ﬁ n e dd i ﬀerent protocols (weekly or every two
weeks) and recipes of multidrug regime to treat diﬀerent
malignancies. The clinical observations from clinical studies
for pegaspargase conjugate are summarized in Table 2 [67,
68].
6.1.3. Mircera (Continuous Erythropoiesis Receptor Activator
or Methoxy Polyethylene Glycol-Epoetin Beta). Mircera is a
PEGylated continuous erythropoietin (EPO) receptor acti-
vator (CERA) introduced by Hoﬀmann-La Roche. It got ap-
proved by FDA in 2007 and is currently used to treat renal
anemia in patients with chronic kidney disease (CKD).
PEGylation of erythropoietin helps to prolong the half-life
to approximately 130h [69]. Darbepoetin alfa (Aranesp,
Amgen), a second-generation EPO, due to the inclusion of
an amino acid mutation has a higher glycosylation rate,
and hence requires only weekly or biweekly injections. On
the other hand, third-generation EPO (CERA) requires only
monthly administration and thus helps in signiﬁcantly im-
proving the quality of life. However, it has been reported to
have negligible eﬀects on morbidity or mortality like other
ESAs [70].
6.1.4.Pegasys(PeginterferonAlfa-2a). Pegasys(peginterferon
alfa-2a) (Hoﬀmann-La Roche) drug is used to treat chronic
hepatitis C (HCV) either alone or in combination with anti-
microbial ribavirin. Pegasys was approved by FDA in 2002. It
consists of a PEGylated interferon alfa-2a intended to medi-
ateantiviralimmuneresponse.PEGylatedinterferondemon-
strated higher eﬃcacy by increasing the clearance time of the
protein, thus maintaining interferon concentration levels in
thebloodtocontrolHCV.Theclinicalstudyofpeginterferon
revealed that 180μg of peginterferon alfa-2a, administered
once a week in patients with hepatitis C-related cirrhosis
or bridging ﬁbrosis was signiﬁcantly more eﬀective than 3
million units of standard interferon alfa-2a [71–73].
6.1.5. PEG-Intron (Peginterferon Alfa-2b). PEG-Intron [74]
marketed by Schering-Plough is used to eradicate hepatic
and extrahepatic hepatitis C virus infection. PEG conjugated
with α-interferon (IFN) was approved by FDA for use in
2001. Monomethoxy-PEG-linked interferon has a sustained
serum for 48–72h compared to the native protein half-life of
7–9h. The recommended dosage for standalone PEG-Intron
therapy is 1mgkg−1 per week for 52 weeks on the same day
of the week subcutaneously [74, 75].
Interestingly, peginterferon α-2a has a higher market
share because peginterferon α-2b is dosed on a body weight
basis, whereas peginterferon α-2a is not. As a result, pegin-
terferon α-2a is more frequently utilized to treat hepatitis CJournal of Drug Delivery 11
Table 2: Clinical trials and their outcome for pegaspargase conjugate.
Stage Trial details Observations/results Reference
Phase I
31 patients with pegaspargase dose ranging from 500 to
8000Um−2.
Mean half-life—357h; dose unrelated hypersensitivity in
small population of patients. [67]
Patients with advanced solid tumors; pegaspargase dose
250–2000Um−2 every 14 days.
L-aspargine level were found to be very low which was
again a function of dose. 2000Um−2 dose showed adverse
eﬀects such as fatigue, nausea/vomiting and weight loss.
Hence dose escalation beyond 2000Um−2 was not
evaluated.
[76]
Low-dose (500 unitsm−2) in children with relapsed
acute lymphoblastic leukemia.
L-asparaginase activity >100UL−1 was demonstrated for
atleast 1 week. Indicating in possibility reduction in dose. [77]
Five patients with AIDS related lymphoma treated with
1500Um−2 every 2 weeks. Three patients showed complete response. [78]
PEG-L-asparaginase as a single agent in patients (22)
with recurrent and/or refractory multiple myeloma.
Maximal tolerated dose for single agent
PEG-L-asparaginase in relapse/refractory multiple
myeloma patients was found to be 1000mgm−2 every 4
weeks.
[79]
Phase II
Patients earlier demonstrated sensitivity to
L-asparaginase was treated with pegaspargase and other
agents.
36% patients demonstrated complete response while 15%
partial response. [80]
Newly diagnosed adults (14) with acute lymphoblastic
leukemia (ALL) treated with 2000Um−2 pegaspargase
and multidrug regimen consisted of vincristine,
prednisone, and danorubicin.
93% patients revealed complete response. [81]
Seven patients with refractory acute leukemias; dose
2000Um−2 on days 1, 14, and 28 with other agents.
Five patients demonstrated complete response while one
showed partial response. [82]
An open-label, multicenter study involving 21 patients
with recurrent lymphoblastic leukemia with
pegaspargase, 2000Um−2 single dose. After 14 days
patients were treated with multidrug therapy regime
consisting of vincristine, prednisone, and some patients
with doxorubicin and intrathecal therapy.
On day 14, 17% of patients (from 18) achieved complete
response and 1% partial response.
On day 35 (after the multidrug regime therapy), 67%
patients demonstrated complete response and 11%
showed partial response. The overall response rate was
78%.
[83]
Pediatric oncology group study: patients with acute
lymphoblastic leukemia treated with 2500Um−2 with
multidrug regime either weekly or every two weeks.
Highly signiﬁcant 93% complete response was observed in
the patients receiving weekly therapy as compared to 82%
in patients receiving every two weeks.
[84]
Phase III
Reinduction of relapsed acute lymphoblastic leukemia:
2500Um−2 pegaspargase on day 1 and 15 or
10,000Um−2 L-asparaginase three times a week for 12
doses, both with multidrug regime.
Despite diﬀerence in dose and dosing rate the complete
response and partial response rates were almost similar
(63 and 65% for pegaspargase and L-asparaginase, resp.).
[85]
Randomized trial involving Children with newly
diagnosed acute lymphoblastic leukemia; 2500Um−2
pegaspargase on day 1 or 6000Um−2L-asparaginase
three times a week for three weeks.
Pegaspargase achieved faster rate of remission. Complete
response rate was almost similar (98% versus 100% for
pegaspargase and L-asparaginase, resp.) despite signiﬁcant
diﬀerence in dose and dosing rates.
[86]
[68]. Nevertheless, some reports have suggested that pegin-
terferon α-ribavirin combination therapy has higher risks
of neutropenia and thrombocytopenia than interferon α-
ribavirin combination therapy [87, 88], although both ther-
apies have been reported to have similar side eﬀect proﬁles.
6.1.6. Somavert (Pegvisomant). Pegvisomant (Somavert)
conjugate (Pﬁzer) is used to treat acromegaly by preventing
human growth hormone (hGH) binding to its receptor, be-
cause this binding activates the signal pathways that lead to
IGF-1 generation. It is a genetically engineered analogue of
hGH conjugated with PEG which was approved for use in
2003[89].Acromegalyisachronicmetabolicdisordercaused
when the pituitary gland generates excess hGH after epi-
physeal plate closure. GH receptor has two binding sites: (i)
binds to site 1 and (ii) then to site 2, inducing the functional
dimerization of the hGH receptor. Pegvisomant inhibits the
dimerizationofthehGHreceptorduetoitsincreasedaﬃnity
for site 1 of the hGH receptor [89]. With eight amino acid
mutations at the site, and by the substitution of position
120 glycine to arginine, inhibits hGH receptor dimerization.
Overall, PEGylation reduces the activity of the GH receptor
antagonist. However, the 4–6 PEG-5000 moieties added to
pegvisomant prolongs its half-life and allow once-daily
administration immunogenicity astherateofclearancefrom
the body are greatly reduced, making it an eﬀective drug
against acromegaly [90]. The recommended dosage for12 Journal of Drug Delivery
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Figure 11: Synthetic structure of pegamotecan, a bisfunctional PEG-CPT conjugate mediated by a glycine spacer.
patients begins with subcutaneous administration of 40mg
dose. The patient can self-administer 10mg of Somavert
daily with adjustments to the dosage of Somavert in 5mg
increments depending on the elevation or decline of insulin
growth factor-1 (IGF-I) levels [91, 92]. However, because
pegvisomantcanincreaseglucosetolerance,careisembarked
for the diabetes mellitus patients [93].
6.1.7. Neulasta (Pegﬁlgrastim). Amgen’s pegﬁlgrastim (Neu-
lasta) is developed using ﬁlgrastim (Neupogen, Amgen)
from Nektar (formerly Shearwater) PEGylation technology.
The conjugate is formed by conjugating a 20kDa linear
monomethoxy-PEG aldehyde with Granulocyte-Colony Sti-
mulatingFactorG-CSF[94].Neulastaisusedtodecreasefeb-
rile neutropenia manifested infection and was approved for
use in 2002. The PEGylation increases the protein serum
half-life to 42h compared to the serum half-life of 3.5–3.8h
for the unmodiﬁed G-CSF. Therefore, the overall dose is
reduced to a single cycle dose that is as eﬀective as daily
doses of native G-CSF [94–96]. The recommended dose of
Neulasta is a single administration of 6mg subcutaneously
once-per-chemotherapy cycle and advised of not delivering
it within 14 days before and 24 days after administration of
chemotherapeutics [97].
6.1.8. Krystexxa (Pegloticase). Krystexxa (pegloticase) by
Savient, a PEGylated mammalian urate oxidase (uricase) was
FDA approved in 2010 [98]. It is a recombinant tetrameric
urate oxidase used for the treatment of chronic gout. Peglot-
icase acts by preventing inﬂammation and pain due to urate
crystal formation in plasma. The advantage of pegloticase
over other standard treatments is the higher eﬀectiveness
in reducing gout tophi [99]. However, pegloticase has been
reported tobe immunogenic. Subcutaneousand intravenous
injections of pegloticase in clinical trials showed production
of antibodies [100–102]. However, it was found out that
the antibodies produced were due to PEG and not because
of uricase. Furthermore, as hydrogen peroxide may be pro-
duced during the conversion of uric acid to allantoin by
uricase, the long-term safety proﬁle of pegloticase needs to
beestablished.Moreover,thetransientlocalpain,slowabsor-
ption, and allergic reactions induced by subcutaneous injec-
tions of pegloticase were not observed after intravenous
injections. However, intravenous injections are administra-
tively inconvenient because self-administration is diﬃcult
and may have caused infusion reactions in multidose trials
[103–105].
6.2. PEG-Drug Conjugates. PEG low-molecular-weight drug
conjugates that entered the clinical trials are mostly from
the camptothecin (CPT) family, namely, camptothecin itself,
SN38,andirinotecan(Table 1).AlthoughtheﬁrstPEGbased
products were anticancer agents, subsequently other PEG
therapeutics were developed and introduced for the treat-
ment, for example, infectious diseases (e.g., PEG-interfe-
rons), and age-related diseases including macular degenera-
tion and arthritis. Moreover, building of these ﬁrst gener-
ation compounds, the pipeline of polymer therapeutics in
clinical development continues to grow.
6.2.1.Prothecan(PEG-Camptothecin). Pegamotecan is a pro-
ductofEnzonPharmaceuticals,Inc.whichisPEGprodrugof
the DNA damaging agent. The prodrug conjugate was con-
ceivedbycouplingtwomoleculesofCPTtoaglycine-bifunc-
tionalised 40kDa PEG, yielding a drug loading of only ap-
proximately1.7%(w/w)[105](Figure 11).TheCPTprodrug
was designed with the aim of doubling the loading capacity
to increase the drug half-life in blood by PEGylation and
to stabilize CPT by acylation of the active lactone conﬁgu-
ration of CPT [105]. The conjugation to PEG considerably
enhancedCPTsolubilityandbioavailabilityatthetumorsite.
The maximum tolerated dose of the conjugate in phase I
trials was determined at 7000mgm−2 when administered for
1hi.v. every 3 weeks, both for heavily and minimally pre-
treated patients. Phase I clinical studies underlined partial
response in some cases and indicated that the conjugation
to PEG notably improved the pharmacokinetics of the com-
pound. Similarly, in phase II studies the same amount and
administration schedule was recommended [106].
6.2.2. NKTR-102 (PEG-Irinotecan). The multiarm PEG
design was employed for the synthesis of NKTR-102 by Nek-
tar Therapeutics in which the drug was conjugated to a
four-arm PEG for the treatment of solid tumors [107]. The
plasma half-life evaluated for NKTR-102 in a mouse model
taking into consideration the active metabolite SN-38,Journal of Drug Delivery 13
released from irinotecan demonstrated prolonged pharma-
cokinetic proﬁle with a half-life of 15 days compared to 4h
with free irinotecan [53]. While in phase I clinical trial the
safety, pharmacokinetic and antitumour activity of NKTR-
102 were evaluated on patients with advanced solid tumors,
(e.g., breast, ovarian, cervical, and non-small-cell lung can-
cer). Interestingly, 13 patients showed signiﬁcant antitumor
activity and reduction of tumor size ranging from a 40% to
58%, while 6 patients showed minor response only [22]. The
cumulative SN38 exposure in patients treated with NKTR-
102 was 1.2- to 6.5-fold higher than that predicted for irino-
tecan. The maximum tolerated dose (MTD) of the conjugate
was to be 115mgm−2 and the toxicity was manageable
(diarrhea and not neutropenia is dose limiting). Noteworthy,
that the patients enrolled in this study had failed the prior
anticancertreatmentsorhavetumorswithnostandardtreat-
ments available. Multiple phase II studies are ongoing with
NKTR-102 alone or in combination with cetuximab for the
treatment of ovarian, breast, colorectal, and cervical cancer
[53].
6.2.3. EZN-2208 (PEG-SN38). The multiarm PEG-SN38
conjugate which recently entered phase I clinical trials (year)
showed an increased drug loading of 3.7wt.% with respect
to pegamotecan. SN38 is an active metabolite of irinotecan
and has 100- to 1000-fold more cytotoxic activity in tissue
cell cultures than irinotecan. However, SN38 is practically
insoluble in water and hence cannot be administered intra-
venously [53]. This PEG conjugation enhanced the solubility
of SN38 by about 1000-fold. The conjugate acts as a prodrug
system with a half-life of 12.3min of SN38 release in
human plasma. Even though the drug release is quite rapid,
the PEG conjugate accumulates in tumor mass by EPR eﬀect.
In fact, EZN-2208 showed a 207-fold higher exposure to
SN38 compared to irinotecan in treated mice, with a tumor
to plasma drug concentration ratio increased over the time
during the four-day-long pharmacokinetic and biodistri-
bution studies [108]. Earlier, the derivatives demonstrated
promising antitumor activity in vitro and in vivo.E s p e c i a l l y ,
in mouse xenograft models of MX-1 breast, MiaPaCa-2 pan-
creatic, or HT-29 colon carcinoma, treatment with the con-
jugate administered either as a single dose or multiple injec-
tions exhibited better results than irinotecan [56]. However,
recently Enzon Pharmaceuticals, Inc. announced the discon-
tinuance of its EZN-2208 clinical program, following con-
clusion of its phase II study. The decision was taken in light
of evolving standards of care for the treatment of metas-
tatic colorectal cancer (mCRC). The company planned to
continue to enroll studies for the other PEG-SN38 programs,
which included a soon-to-be fully enrolled phase II study in
metastatic breast cancer, a phase I study in pediatric cancer,
and a phase I study in combination with Avastin (beva-
cizumab injection) in solid tumors [109].
7.ClinicalPerspective
Early polymer therapeutics were developed as treatments for
life-threatening diseases (cancer and infectious diseases), the
emerging products, and clinical development candidates are
designed for a much broader range of diseases. NKTR194, an
opioiddrug,beingdevelopedbyNektarusingtheiradvanced
polymer conjugate technology platform is presently in the
preclinical stage [110]. It has been designed to act periph-
erally without entering the CNS so that the gastrointestinal
bleeding, CNS side eﬀects, and cardiovascular risks associate
with NSAIDs and COX-2 inhibitors used for treating mod-
erate pains. NKTR-171 is another drug being designed by
Nektar to treat neuropathic pain without CNS side eﬀects is
in the early research stage. NKTR-125 also in the research
stage combines Nektar’s PEGylation technology with potent
antihistamine to enhance its anti-inﬂammatory properties
and minimize the side eﬀects.
BAX 855, Baxter’s most advanced longer-acting can-
didate, is schedule to move into phase I clinical trial in
2011 [110]. It is a PEGylated FVIII molecule, which utilizes
Nektar’s PEGylation and Baxter’s proprietary plasma and
albumin-free platform. Preclinical animal studies have re-
vealed that 1 injection of BAX 855 per week imparted similar
FVIII levels as that of 3 injections of Advate given approx-
imately every alternate day. In addition, Nektar and Baxter
have collaborated to design long-acting clotting protein for
hemophilia using Nektar’s innovative PEGylation and re-
leasable linker conjugate technology [110].
Convincingly, there are pioneering new approaches in
research, for example, PEG-recombinant human HA-degra-
ding enzyme, (rHuPH20) developed to degrade HA (it often
accumulates in the tumor interstitium) with the aim of dec-
reasing interstitial tumor pressure and to enhance penetra-
tion of both low-molecular-weight and nanosized anticancer
agents [111, 112]. The latter provides an interesting oppor-
tunity for combination therapy.
8. Conclusions
PEG is currently the only water soluble polymer, widely
accepted in therapeutics with market approval for diﬀerent
drugs. The reason for the wide utility of PEG is because its
decreased interaction with blood components (low plasma
proteinbinding)andhighbiocompatibility.PEGylateddrugs
such as peginterferon α and pegﬁlgrastim have proven their
cost-eﬀectiveness in the market, and products like pegvi-
somant and certolizumab pegol demonstrate that PEGylated
forms will be marketed regardless of the prior commercial-
izationoftheirnon-PEGylatedcounterparts.Thistrendindi-
cates that the long-term prospects for the biopharmaceutical
PEGylatedproteinmarketarehigh.Duetosigniﬁcantclinical
advantages, PEGylation is an essential proposition in deliv-
ering drugs and other bioactives. The therapeutic advan-
tages of G-CSF, IFN, and EPO have been acknowledged, and
PEGylation oﬀers an attractive means of replacing the origi-
nalmarket,giventheassumptionthatbiosimilarswillappear
soon afterpatents expire. Moreover, PEGylation allows drugs
to be distinguished from simple biosimilars. The critical per-
spective of PEGylation is now envisioned to achieve cellu-
lar targetability and therefore suitable chemistry is being
explored. Advanced forms of PEGs and their various archi-
tectures are designed and being introduced (e.g., hyper14 Journal of Drug Delivery
branched polyglycerols) [113]. Therefore, the importance of
conducting comprehensive investigations on recently intro-
duced potent peptides, proteins, oligonucleotides, and anti-
body fragments for PEGylation cannot be overemphasized.
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